{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T20:35:45Z","timestamp":1792787745531,"version":"4.5.0"},"reference-count":33,"publisher":"SAGE Publications","license":[{"start":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T00:00:00Z","timestamp":1791417600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T00:00:00Z","timestamp":1791417600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"funder":[{"name":"Health Resources and Services Administration","award":["5UT8HA33951"],"award-info":[{"award-number":["5UT8HA33951"]}],"id":[{"id":"https:\/\/ror.org\/0121dpf30","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["AIDS Patient Care and STDs"],"abstract":"<jats:p>Long-acting injectable cabotegravir (CAB-LA) may be particularly advantageous for preventing HIV among people experiencing homelessness (PEH) and people who use drugs (PWUD), populations at high HIV risk with poor oral pre-exposure prophylaxis (PrEP) outcomes. In a retrospective study using the RE-AIM framework to organize programmatic outcomes, we evaluated real-world implementation of CAB-LA at the Maria X. Martinez Health Resource Center, a status-neutral, fully drop-in municipal clinic in San Francisco, CA, serving &gt;4000 patients annually for diverse health needs. We included all patients prescribed CAB-LA between October 2022 and December 2025. Outcomes included reach, adoption, implementation (injection timeliness, delivery setting, guideline-concordant HIV monitoring), maintenance (retention), and exploratory effectiveness (HIV acquisitions relative to active coverage). Nineteen providers prescribed CAB-LA to 68 patients (63% experiencing homelessness; 56% with stimulant use disorder, 34% opioid use disorder, 51% psychotic-spectrum illness); 52 (76%) received \u22651 injection. Of 304 injections, 42% occurred outside the clinic, including in shelters, on the street, and in jail or inpatient settings; 76% of follow-up injections were on time. HIV testing concordant with the Centers for Disease Control and Prevention guidelines (antigen\/antibody plus RNA) accompanied 37% of injections. Twelve-month retention was 49%. Two patients acquired HIV, both during gaps in CAB-LA coverage. Sustaining coverage required intensive outreach, population tracking, insurance reenrollment, and financial incentives. Findings suggest that CAB-LA can be delivered in a fully drop-in clinic serving PEH and PWUD, while highlighting the resource-intensive support required to maintain coverage. Adapting delivery models, laboratory monitoring protocols, and financing to the realities of structurally vulnerable populations is essential to extend the benefits of long-acting PrEP.<\/jats:p>","DOI":"10.1177\/10872914261494329","type":"journal-article","created":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T07:55:48Z","timestamp":1791446148000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":0,"title":["Delivering Long-Acting Injectable Cabotegravir PrEP to People Experiencing Homelessness and People Who Use Drugs"],"prefix":"10.1177","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4277-6889","authenticated-orcid":false,"given":"Nicky J.","family":"Mehtani","sequence":"first","affiliation":[{"name":"Whole Person Integrated Care, San Francisco Department of Public Health, San Francisco, California, USA."},{"name":"Department of Medicine, University of California, San Francisco, San Francisco, California, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen J.","family":"Matzat","sequence":"additional","affiliation":[{"name":"Whole Person Integrated Care, San Francisco Department of Public Health, San Francisco, California, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anoushka","family":"Rustagi","sequence":"additional","affiliation":[{"name":"Whole Person Integrated Care, San Francisco Department of Public Health, San Francisco, California, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hannah","family":"Stowe","sequence":"additional","affiliation":[{"name":"Whole Person Integrated Care, San Francisco Department of Public Health, San Francisco, California, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Strieff","sequence":"additional","affiliation":[{"name":"Whole Person Integrated Care, San Francisco Department of Public Health, San Francisco, California, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-2486-6817","authenticated-orcid":false,"given":"Derek","family":"Sportsman","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of California, San Francisco, San Francisco, California, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Morgan M.","family":"Philbin","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of California, San Francisco, San Francisco, California, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monica","family":"Gandhi","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of California, San Francisco, San Francisco, California, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mallory O.","family":"Johnson","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of California, San Francisco, San Francisco, California, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2026,10,8]]},"reference":[{"key":"e_1_3_3_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3018(25)00048-7"},{"key":"e_1_3_3_3_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2018.1917"},{"key":"e_1_3_3_4_1","doi-asserted-by":"publisher","DOI":"10.2105\/AJPH.2021.306208"},{"key":"e_1_3_3_5_1","doi-asserted-by":"publisher","DOI":"10.1377\/hlthaff.2023.00867"},{"key":"e_1_3_3_6_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11904-024-00714-z"},{"key":"e_1_3_3_7_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2101016"},{"key":"e_1_3_3_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(22)00538-4"},{"key":"e_1_3_3_9_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2024.24543"},{"key":"e_1_3_3_10_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0000000000003396"},{"key":"e_1_3_3_11_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11606-025-09350-8"},{"key":"e_1_3_3_12_1","doi-asserted-by":"publisher","DOI":"10.1089\/apc.2024.0048"},{"key":"e_1_3_3_13_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2026.20699"},{"issue":"1","key":"e_1_3_3_14_1","article-title":"508. Cabotegravir long-acting for Pre-Exposure Prophylaxis (PrEP): Real world data on on-time dosing, HIV testing and HIV acquisition from the OPERA cohort","volume":"12","author":"Mills AM","year":"2025","unstructured":"13.Mills AM, , Brunet L, , Frost KR, et al. 508. Cabotegravir long-acting for Pre-Exposure Prophylaxis (PrEP): Real world data on on-time dosing, HIV testing and HIV acquisition from the OPERA cohort. Open Forum Infect Dis 2025;12(Suppl 1):pofae631-160.","journal-title":"Open Forum Infect Dis"},{"issue":"1","key":"e_1_3_3_15_1","article-title":"505. Real-world use of cabotegravir long-acting for pre-exposure prophylaxis: Data from trio health cohort","volume":"12","author":"Ramgopal M","year":"2025","unstructured":"14.Ramgopal M, , Brown CA, , Frick A, et al. 505. Real-world use of cabotegravir long-acting for pre-exposure prophylaxis: Data from trio health cohort. Open Forum Infect Dis 2025;12(Suppl 1):ofae631-157.","journal-title":"Open Forum Infect Dis"},{"key":"e_1_3_3_16_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0000000000003889"},{"key":"e_1_3_3_17_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciae531"},{"key":"e_1_3_3_18_1","doi-asserted-by":"publisher","DOI":"10.1002\/jia2.26497"},{"key":"e_1_3_3_19_1","doi-asserted-by":"publisher","DOI":"10.1177\/23259582261420655"},{"key":"e_1_3_3_20_1","doi-asserted-by":"publisher","DOI":"10.2105\/AJPH.89.9.1322"},{"key":"e_1_3_3_21_1","unstructured":"20.Centers for Disease Control and Prevention: US Public Health Service. Preexposure prophylaxis for the prevention of HIV infection in the United States\u20142021: Clinical practice guideline. 2021. Available from: https:\/\/stacks.cdc.gov\/view\/cdc\/112360"},{"key":"e_1_3_3_22_1","volume-title":"Guidelines on long-acting injectable cabotegravir for HIV prevention","author":"World Health Organization","year":"2022","unstructured":"21.World Health Organization. Guidelines on long-acting injectable cabotegravir for HIV prevention. WHO: Geneva; 2022. Available from: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK586585\/"},{"key":"e_1_3_3_23_1","volume-title":"Guidelines on lenacapavir for HIV prevention and testing strategies for long-acting injectable pre-exposure prophylaxis","author":"World Health Organization","year":"2025","unstructured":"22.World Health Organization. Guidelines on lenacapavir for HIV prevention and testing strategies for long-acting injectable pre-exposure prophylaxis. WHO: Geneva; 2025. Available from: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK616663\/"},{"key":"e_1_3_3_24_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2026.20348"},{"key":"e_1_3_3_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.socscimed.2021.113809"},{"key":"e_1_3_3_26_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciae648"},{"key":"e_1_3_3_27_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciaf173"},{"key":"e_1_3_3_28_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1005030"},{"key":"e_1_3_3_29_1","unstructured":"28.Landovitz R Gao F Fogel JM et al. Performance characteristics of HIV RNA screening with long-acting injectable cabotegravir (CAB-LA) Pre-Exposure Prophylaxis (PrEP) in the multicenter global HIV Prevention Trials Network 083 (HPTN 083) study. In: IAS 25th International AIDS Conference. AIDS; 2024."},{"key":"e_1_3_3_30_1","doi-asserted-by":"publisher","DOI":"10.1089\/apc.2023.0211"},{"key":"e_1_3_3_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2468-1253(21)00397-6"},{"key":"e_1_3_3_32_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11904-022-00624-y"},{"key":"e_1_3_3_33_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2407001"},{"key":"e_1_3_3_34_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2411858"}],"container-title":["AIDS Patient Care and STDs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10872914261494329","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/10872914261494329","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10872914261494329","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,11]],"date-time":"2026-10-11T13:46:39Z","timestamp":1791726399000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/10872914261494329"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,8]]},"references-count":33,"alternative-id":["10.1177\/10872914261494329"],"URL":"https:\/\/doi.org\/10.1177\/10872914261494329","relation":{},"ISSN":["1087-2914","1557-7449"],"issn-type":[{"value":"1087-2914","type":"print"},{"value":"1557-7449","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,8]]},"article-number":"10872914261494329"}}